With the exception of ALK (anaplastic lymphoma kinase) positive anaplastic large cell lymphoma, PTCL exhibits an aggressive course and patients have a poor outcome after conventional chemotherapy[4-7] with a median overall survival (OS) of 9 to 42 months[8-10]. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.